Jurka, P. and A. Max (2009). “Treatment of fibroadenomatosis in 14 cats with aglespristone – changes in blood parameters and follow-up.” Vet Record 165(22): 657-660.
Mammary hyperplasia (also called fibroadenomatosis or fibroadenomatous hyperplasia) is a benign inflammatory condition commonly seen in young cycling queens. It may also be seen in pregnant queens, and in male or female cats treated with progestins. The hyperplasia can be severe, leading to tissue necrosis, ulceration and infection. The etiology is suspected to be an exaggerated response to natural progesterone or synthetic progestins, but the disease is also rarely reported in sterilized male or female cats with no history of progestin therapy. In spayed queens, ovarian remnant syndrome may be the initiating cause. Many drug therapies have been tried, but the current drug of choice is the progesterone receptor blocker aglepristone (Alizine®, Virbac). Widely available in many countries around the world, it is not available in North America. The drug is also used for pregnancy termination and treatment of cystic endometrial hyperplasia/pyometra complex. The researchers, based in Warsaw, diagnosed 14 female cats with mammary hyperplasia and treated them with aglepristone. The cats were followed up for 12 months after the end of treatment. On average, complete clinical remission of the mammary hyperplasia was achieved 3.9 weeks after initiation of treatment. If the cat had been previously treated with a progestin, a longer treatment period with aglepristone was recommended. After treatment, six queens were bred and four successfully produced at least one litter of kittens. This research confirms the safety and efficacy of aglepristone for treatment of mammary hyperplasia in cats. [SL]
>> Journal Abstract
Gorlinger, S., H. S. Kooistra, et al. (2002). “Treatment of fibroadenomatous hyperplasia in cats with aglepristone.” J Vet Intern Med 16(6): 710-3.
>> PubMed Abstract
Nak, D., Y. Nak, et al. (2009). “Follow-up examinations after medical treatment of pyometra in cats with the progesterone-antagonist aglepristone.” Journal of Feline Medicine & Surgery 11(6): 499-502.
>> Pubmed Abstract